Zymeworks Inc. Announces the Addition of Lota S. Zoth to Its Board of Directors

VANCOUVER, British Columbia--()--Zymeworks Inc., a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation bispecific and multifunctional biotherapeutics, initially focused on the treatment of cancer, announced today that Ms. Lota S. Zoth, CPA, has joined the Company’s Board of Directors.

“We are excited to welcome Lota to the Zymeworks team,” said Ali Tehrani, Ph.D., Zymeworks’ President & CEO. “Her breadth of knowledge and years of experience working with growing, dynamic companies will provide valuable insight at the board level as we continue to execute our corporate objectives.”

Ms. Zoth has extensive experience serving in senior financial and operational roles at a variety of companies across various industries over her 34-year career, including serving as Chief Financial Officer for MedImmune before its acquisition by AstraZeneca in 2007. Ms. Zoth has served as a member of multiple public and private company boards over the past decade in the biopharmaceutical industry.

“Becoming part of the Zymeworks team at this stage of their lifecycle is invigorating,” said Ms. Zoth. “I look forward to providing useful perspectives and expertise developed from my past experiences to the team and the board, as development of these innovative biotherapeutics moves forward.”

Zymeworks would also like to thank Mr. Amos Michelson for his years of service as a member of the Zymeworks’ Board of Directors. Concurrent with Ms. Zoth’s appointment, Mr. Michelson will be stepping down as a member of the Board of Directors.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation bispecific and multifunctional biotherapeutics, initially focused on the treatment of cancer. The Company’s Azymetric™, AlbuCORE™, and EFECT™ platforms, its Zymelink™ conjugation platform and cytotoxins, and its proprietary ZymeCAD™ structure-guided protein engineering technology, provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates. The Company’s lead product candidate, ZW 25, is a novel bispecific antibody being evaluated in a Phase 1 clinical trial. Zymeworks is also advancing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. In addition to the Company’s wholly-owned pipeline, its therapeutic platforms have been further leveraged through multiple strategic partnerships with global biopharmaceutical companies. More information on Zymeworks can be found at www.zymeworks.com.

Contacts

Zymeworks Inc.
Investor Inquiries
David Matousek, (604) 678-1388
Senior Manager, Investor Relations & Corporate Communications
ir@zymeworks.com
or
Media Inquiries
Michael Lampe, (484) 575-5040
michael@scientpr.com

Contacts

Zymeworks Inc.
Investor Inquiries
David Matousek, (604) 678-1388
Senior Manager, Investor Relations & Corporate Communications
ir@zymeworks.com
or
Media Inquiries
Michael Lampe, (484) 575-5040
michael@scientpr.com